Canadian Pharmacists Journal - May/June 2019 - 176

PRACTiCeTOOL

176



36. Strach K, Schrock A, Wilhelm K, et al. Endovascular
treatment of epistaxis: indications, management and outcome. Cardiovasc Intervent Radiol 2011;34(6):1190-8.
37. Strong EB, Bell DA, Johnson LP, Jacobs JM. Intractable epistaxis: transantral ligation vs. embolization: efficacy review and cost analysis. Otolaryngol Head Neck Surg
1995;113(6):674-8.
38. Cote D, Barber B, Diamond C, Wright E. FloSeal hemostatic matrix in persistent epistaxis: prospective clinical trial.
J Otolaryngol Head Neck Surg 2010;39(3):304-8.
39. Khan MK, Reda El, Badawey M, Powell J, Idris M. The
utility of FloSeal haemostatic agent in the management of
epistaxis. J Laryngol Otol 2015;129(4):353-7.
40. Kilty SJ, AlHajry M, AlMutairi D, et al. Prospective clinical trial of gelatin-thrombin matrix as first line treatment of
posterior epistaxis. Laryngoscope 2014;124(1):38-42.
41. Lau AS, Upile NS, Lazarova L, Swift AC. Evaluating the
use of Floseal haemostatic matrix in the treatment of epistaxis: a prospective, control-matched longitudinal study.

medication. Eur Arch Otorhinolaryngol 2016;273(9):
2561-7.
53. Smith J, Siddiq S, Dyer C, Rainsbury J, Kim D. Epistaxis
in patients taking oral anticoagulant and antiplatelet medication: prospective cohort study. J Laryngol Otol 2011;125(1):
38-42.
54. Tay HL, McMahon AD, Evans JMM, MacDonald TM.
Aspirin, nonsteroidal anti-inflammatory drugs and epistaxis:
a regional record linkage case control study. Ann Otol Rhinol
Laryngol 1998;107(8):671-4.
55. Garcia Callejo FJ, Becares Martinez C, Calvo Gonzalez
J, Martinez Beneyto P, Marco Sanz M, Marco Algarra J. Epistaxis and dabigatran, a new non-vitamin K antagonist oral
anticoagulant. Acta Otorrinolaringol Esp 2014;65(6):346-54.
56. White PJ. Patient factors that influence warfarin dose
response. J Pharm Pract 2010;23(3):194-204.
57. Choudhury N, Sharp HR, Mir N, Salama NY. Epistaxis
and oral anticoagulant therapy. Rhinology 2004;42(2):92-7.
58. Musgrave KM, Powell J. A systematic review of anti-throm-

Eur Arch Otorhinolaryngol 2016;273(9):2579-84.
42. Mathiasen RA, Cruz RM. Prospective, randomized,
controlled clinical trial of a novel matrix hemostatic sealant in patients with acute anterior epistaxis. Laryngoscope
2005;115(5):899-902.
43. Wakelam OC, Dimitriadis PA, Stephens J. The use of
FloSeal haemostatic sealant in the management of epistaxis:
a prospective clinical study and literature review. Ann R Coll
Surg Engl 2017;99(1):28-30.
44. Walshe P. The use of fibrin glue to arrest epistaxis in the
presence of a coagulopathy. Laryngoscope 2002;112(6):1126-8.
45. Faber C, Larson K, Amirlak B, Guyuron B. Use of
desmopressin for unremitting epistaxis following septorhinoplasty and turbinectomy. Plast Reconstr Surg 2011;
128(6):728e-32e.
46. Derkay CS, Hirsch BE, Johnson JT, Wagner RL. Posterior
nasal packing: are intravenous antibiotics really necessary?
Arch Otolaryngol Head Neck Surg 1989;115(4):439-41.
47. Baxter II. Floseal Hemostatic matrix: instructions for use.
2014. Available: http://www.baxter.ca/en_CA/assets/downloads/
monographs/Floseal%20FinalArtwork_0726933 _23FEB2015_
footer%20removed.pdf (accessed October 3, 2017).
48. Omrix Biopharmaceuticals L. Evicel: product monograph.
2017. Available: https://pdf.hres.ca/dpd_pm/00041607.PDF
(accessed Oct. 2017).
49. Baxter C. Tisseel: product monograph. 2016. Available:
https://pdf.hres.ca/dpd_pm/00035795.PDF (accessed Oct. 2017).
50. Biswas D, Mal RK. Are systemic prophylactic antibiotics
indicated with anterior nasal packing for spontaneous epistaxis? Acta Otolaryngol 2009;129(2):179-81.
51. Soyka MB, Rufibach K, Huber A, Holzmann D. Is severe
epistaxis associated with acetylsalicylic acid intake? Laryngoscope 2010;120(1):200-7.
52. Stadler RR, Kindler R, Holzmann D, Soyka MB. The longterm fate of epistaxis patients with exposure to antithrombotic

botic therapy in epistaxis. Rhinology 2016;54(4):292-391.
59. Srinivasan V, Patel H, John DG, Worsley A. Warfarin and
epistaxis: should warfarin always be discontinued? Clin Otolaryngol Allied Sci 1997;22(6):542-4.
60. Biggs TC, Baruah P, Mainwaring J, Harries PG, Salib RJ.
Treatment algorithm for oral anticoagulant and antiplatelet
therapy in epistaxis patients. J Laryngol Otol 2013;127(5):483-8.
61. Utkewicz MD, Brunetti L, Awad NI. Epistaxis complicated by rivaroxaban managed with topical tranexamic acid.
Am J Emerg Med 2015;33(9):1329.e5-e7.
62. Chen BC, Viny AD, Garlich FM, et al. Hemorrhagic
complications associated with dabigatran use. Clin Toxicol
2012;50(9):854-7.
63. Sennesael AL, Dogne JM, Spinewine A. Optimizing the
safe use of direct oral anticoagulants in older patients: a
teachable moment. JAMA Intern Med 2015;175(10):1608-9.
64. Stollberger C, Krutisch G, Finsterer J. Life-threatening
epistaxis and red blood cell polyagglutination under dabigatran. Blood Coagul Fibrinolysis 2014;25(4):384-6.
65. Freshour JE, Hudson JQ, Stevens AB, Franks AS. Epistaxis associated with dabigatran in an elderly patient with
reduced creatinine clearance. Am J Health Syst Pharm
2012;69(14):1184-6.
66. Gruenebaum DD, Alsarah A, Alsara O, Laird-Fick H.
Bleeding complication of triple therapy of rivaroxaban, prasugrel and aspirin: a case report and general discussion. Case
Rep Cardiol 2014;2014:293476.
67. Gage BF, Waterman AD, Shannon W, Boechler M,
Rich MW, Radford MJ. Validation of clinical classification
schemes for predicting stroke: results from the National
Registry of Atrial Fibrillation. JAMA 2001;285(22):2864-70.
68. Hassenplug KL, Burkiewicz JS, Jackson TL, Peppers
LR. Educating patients in self-management of epistaxis
in an anticoagulation clinic. Am J Health Syst Pharm
2006;63(10):909-11.

C P J / R P C  *  M ay / J u n e  2 0 1 9  *  V O L  1 5 2 ,  N O  3
https://www.baxter.ca/en_CA/assets/downloads/monographs/FlosealFinalArtwork_0726933_23FEB2015_footerremoved.pdf https://www.baxter.ca/en_CA/assets/downloads/monographs/FlosealFinalArtwork_0726933_23FEB2015_footerremoved.pdf https://www.baxter.ca/en_CA/assets/downloads/monographs/FlosealFinalArtwork_0726933_23FEB2015_footerremoved.pdf https://pdf.hres.ca/dpd_pm/00041607.PDF https://pdf.hres.ca/dpd_pm/00035795.PDF
Canadian Pharmacists Journal - May/June 2019

Table of Contents for the Digital Edition of Canadian Pharmacists Journal - May/June 2019
